



Grant of Options and Restricted Stock Units

October 18, 2024 8:24 AM EDT

RNS Number : 77261
MaxCyte, Inc.
18 October 2024



MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options and Restricted Stock Units

ROCKVILLE, MD, October 18, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 October 2024, Cynthia Collins, a non-executive director, has been granted total of 97,698 options ("Option Grant") in respect of common stock in the Company ("Common Stock"), and 51,679 restricted stock units ("RSU"s), which were agreed in September pursuant to Cynthia's appointment.

The Option Grant vests over three (3) years, with the initial vesting of 1/3rd of the total after twelve (12) months, and the remainder vesting monthly over the following 24 months. The Option Grant have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 14 October 2024, of \$3.87 on the United States Nasdaq Stock Exchange.

The RSUs vest at the end of twelve (12) months after date of grant. (1 year cliff until fully vested).

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on [Twitter](#) and [LinkedIn](#).

MaxCyte Contacts:

US IR Adviser

Gilmartin Group
David Deuchler, CFA

+1 415-937-5400
ir@maxcyte.com

**Nominated Adviser and Joint
Corporate Broker**
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh

+44 (0)203 709 5700
maxcyte@consilium-comms.com

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Cynthia Collins
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Common Stock of \$0.01 each US57777K1060
b)	Nature of the transaction	Grant of options of common stock
c)	Price(s) and volume(s)	97,698 Options at an exercise price of \$3.87
d)	Aggregated information - Aggregated volume - Price	 N/A N/A

e)	Date of the transaction	14 October 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Cynthia Collins
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Grant of restricted stock units US57777K1060
b)	Nature of the transaction	Grant of options of restricted stock units
c)	Price(s) and volume(s)	51,679 restricted stock units, price N/A
d)	Aggregated information - Aggregated volume - Price	 N/A N/A
e)	Date of the transaction	14 October 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lsej.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHGIBDGBDBDGS